Adding a new drug to capecitabine for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and your cancer is confirmed by tissue testing as metastatic or unresectable
- Your cancer has gotten worse after standard treatments that included 5-FU or capecitabine
- You have measurable disease (doctors can track it on scans or tests)
- You must have enough healthy blood and organ function (blood counts, liver enzymes, kidneys)
- You must be able and willing to get tumor biopsies (before treatment, and again during treatment for colorectal cancer)
- You must not have had treatment with BET inhibitors before, and you must be able to take capecitabine as planned
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
This trial tests a new combination drug, LBL-024, for people with colorectal cancer that has spread to other parts of the body. The goal is to see if the combination can shrink tumors or slow down the cancer's growth.
This study tests two new drugs, zanzalintinib and MO-03, for people whose kidney cancer has grown after treatment with immunotherapy and cabozantinib. The goal is to see if combining these drugs helps control the cancer.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.